# Quarterly condensed consolidated financial

## statements

For the three-month period ended 31 March 2022 (unaudited)

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT

| \$ millions   | Note | 31 March<br>2022 | 31 December<br>2021 |
|---|------|------------------|---------------------|
| \$ minors   | Note | LULL             | 2021                |
| Assets  |      |                  |                     |
| Non-current assets  |      |                  |                     |
| Property, plant and equipment                                     | (8)  | 5,418.6          | 5,543.5             |
| Right-of-use assets   |      | 250.3            | 248.2               |
| Goodwill and other intangible assets                              | (9)  | 485.0            | 485.7               |
| Trade and other receivables                                       |      | 34.2             | 33.6                |
| Equity-accounted investees  |      | 563.3            | 494.9               |
| Financial assets at fair value through other comprehensive income |      | 21.7             | 19.2                |
| Deferred tax assets   | (15) | 182.9            | 207.7               |
| Total non-current assets  |      | 6,956.0          | 7,032.8             |
| Current assets  |      |                  |                     |
| Inventories   |      | 517.5            | 343.5               |
| Trade and other receivables                                       |      | 1,058.6          | 851.6               |
| Income tax receivables  |      | 3.7              | 3.4                 |
| Cash and cash equivalents   |      | 1,759.0          | 1,580.3             |
| Total current assets  |      | 3,338.8          | 2,778.8             |
| Total assets  |      | 10,294.8         | 9,811.6             |

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION CONTINUED AS AT

| \$ millions                                  | Note | 31 March<br>2022 | 31 December<br>2021 |
|--|------|------------------|---------------------|
| Equity                                       |      |                  |                     |
| Share capital                                |      | 5.6              | 5.6                 |
| Share premium                                |      | 6,316.3          | 6,316.3             |
| Reserves                                     |      | (372.3)          | (384.0)             |
| Retained earnings                            |      | (3,310.0)        | (3,938.9)           |
| Equity attributable to owners of the Company |      | 2,639.6          | 1,999.0             |
| Non-controlling interests                    | (10) | 1,740.8          | 1,509.2             |
| Total equity                                 |      | 4,380.4          | 3,508.2             |
| Liabilities                                  |      |                  |                     |
| Non-current liabilities                      |      |                  |                     |
| Loans and borrowings                         | (11) | 2,724.1          | 3,290.2             |
| Lease obligations                            |      | 238.2            | 237.5               |
| Trade and other payables                     | (12) | 129.9            | 23.7                |
| Provisions                                   |      | 12.8             | 12.8                |
| Deferred tax liabilities                     | (15) | 647.0            | 614.4               |
| Total non-current liabilities                |      | 3,752.0          | 4,178.6             |
| Current liabilities                          |      |                  |                     |
| Loans and borrowings                         | (11) | 295.4            | 510.6               |
| Lease obligations                            |      | 43.6             | 39.7                |
| Trade and other payables                     | (12) | 1,595.9          | 1,357.5             |
| Provisions                                   | (17) | 129.0            | 144.7               |
| Income tax payables                          | (15) | 98.5             | 72.3                |
| Total current liabilities                    |      | 2,162.4          | 2,124.8             |
| Total liabilities                            |      | 5,914.4          | 6,303.4             |
| Total equity and liabilities                 |      | 10,294.8         | 9,811.6             |

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THREE-MONTH PERIOD ENDED 31 MARCH

| \$ millions  | Note | Three-month<br>period ended<br>31 March 2022 | Three-month<br>period ended<br>31 March 2021 |
|--|------|--|--|
| Revenue  | (16) | 2,327.8                                      | 1,119.6                                      |
| Cost of sales  | (13) | (1,464.3)                                    | (779.2)                                      |
| Gross profit   |      | 863.5  | 340.4  |
| Other income   |      | 4.6  | 0.9  |
| Selling, general and administrative expenses   | (13) | (78.4)                                       | (60.6)                                       |
| Other expenses   |      | -  | (0.1)  |
| Operating profit   |      | 789.7  | 280.6  |
| Finance income   | (14) | 72.2   | 8.1  |
| Finance cost   | (14) | (85.6)                                       | (74.8)                                       |
| Net finance cost   | (14) | (13.4)                                       | (66.7)                                       |
| Income from equity-accounted investees (net of tax)  | \ /  | 62.9   | 0.7  |
| Profit before income tax   |      | 839.2  | 214.6  |
| Income tax   | (15) | (140.0)                                      | (30.1)                                       |
| Net profit   |      | 699.2  | 184.5  |
| Other comprehensive income:<br>Items that are or may be reclassified subsequently to profit or loss                    |      | 10.0   | (5.0)  |
| Movement in hedge reserve  |      | 16.8   | (5.9)  |
| Currency translation differences   |      | (31.9)                                       | (20.2)                                       |
| Currency translation differences from equity-accounted investees Items that will not be reclassified to profit or loss |      | (1.1)  | (0.6)  |
| •  |      | 2.6  | (1 0)  |
| Changes in the fair value of financial assets at fair value through other comprehensive income                         |      | (13.6)                                       | (1.2)  |
| Other comprehensive income, net of tax Total comprehensive income  |      | 685.6  | (27.9)                                       |
|  |      | 005.0  | 150.0  |
| Profit attributable to:  |      |  |  |
| Owners of the Company  |      | 409.7  | 98.6   |
| Non-controlling interests  |      | 289.5  | 85.9   |
| Net profit   |      | 699.2  | 184.5  |
| Total comprehensive income attributable to:  |      |  |  |
| Owners of the Company  |      | 417.2  | 77.5   |
| Non-controlling interests  |      | 268.4  | 79.1   |
| Total comprehensive income   |      | 685.6  | 156.6  |
| Earnings per share (in USD)  |      |  |  |
| Basic earnings per share   |      | 1.952  | 0.470  |
| Diluted earnings per share   |      | 1.942  | 0.468  |

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

| \$ millions   | Note | Share capital | Share premium | Reserves | Retained earnings | Equity attributable<br>to owners of the<br>Company | Non-controlling<br>interests | Total<br>equity |
|---|------|---------------|---------------|----------|-------------------|--|------------------------------|-----------------|
| Balance at 1 January 2021                                     |      | 5.6           | 6,316.3       | (338.4)  | (4,851.8)         | 1,131.7  | 1,540.1                      | 2,671.8         |
| Net profit  |      | -             | -             | -        | 98.6              | 98.6   | 85.9                         | 184.5           |
| Other comprehensive income                                    |      | -             | -             | (21.1)   | -                 | (21.1)   | (6.8)                        | (27.9)          |
| Total comprehensive income                                    |      | -             | -             | (21.1)   | 98.6              | 77.5   | 79.1                         | 156.6           |
| Impact difference in profit sharing non-controlling interests |      | -             | -             | -        | -                 | -  | 13.0                         | 13.0            |
| Dividend to non-controlling interest                          |      | -             | -             | -        | -                 | -  | (23.1)                       | (23.1)          |
| Share-based payments  |      | -             | -             | -        | 2.0               | 2.0  | -                            | 2.0             |
| Balance at 31 March 2021                                      |      | 5.6           | 6,316.3       | (359.5)  | (4,751.2)         | 1,211.2  | 1,609.1                      | 2,820.3         |

| Balance at 1 January 2022                                     |      | 5.6 | 6,316.3 | (384.0) | (3,938.9) | 1,999.0 | 1,509.2 | 3,508.2 |
|---|------|-----|---------|---------|-----------|---------|---------|---------|
| Net profit  |      | -   | -       | _       | 409.7     | 409.7   | 289.5   | 699.2   |
| Other comprehensive income                                    |      | -   | -       | 7.5     | -         | 7.5     | (21.1)  | (13.6)  |
| Total comprehensive income                                    |      | -   | -       | 7.5     | 409.7     | 417.2   | 268.4   | 685.6   |
| Impact difference in profit sharing non-controlling interests |      | -   | -       | _       | -         | -       | 60.3    | 60.3    |
| Dividend to non-controlling interests                         |      | -   | -       | -       | -         | -       | (104.9) | (104.9) |
| Treasury shares sold / delivered                              |      | -   | -       | 4.4     | (4.4)     | -       | -       | -       |
| Treasury shares acquired                                      |      | -   | -       | (0.2)   | -         | (0.2)   | -       | (0.2)   |
| Sale of shares in OCI Methanol Group <sup>1</sup>             | (10) | -   | -       | -       | 221.4     | 221.4   | 7.8     | 229.2   |
| Share-based payments  |      | -   | -       | -       | 2.2       | 2.2     | -       | 2.2     |
| Balance at 31 March 2022                                      |      | 5.6 | 6,316.3 | (372.3) | (3,310.0) | 2,639.6 | 1,740.8 | 4,380.4 |

<sup>1</sup> The sale of shares in OCI Methanol Group includes a dividend liability of USD 144.5 million; an amount of USD 17.1 million attributable to shareholder's equity and an amount of USD 127.4 million to non-controlling interests. Reference is made to note 10 and 12.

## **CONSOLIDATED STATEMENT OF CASH FLOWS** FOR THE THREE-MONTH PERIOD ENDED 31 MARCH

| \$ millions   | Note | Three-month<br>period ended<br>31 March 2022 | Three-month<br>period ended<br>31 March 2021 |
|---|------|--|--|
| Net profit  |      | 699.2  | 184.5  |
| Adjustments for:  |      |  |  |
| Depreciation, amortization and impairment                     | (13) | 146.0  | 150.2  |
| Interest income   | (14) | (2.7)  | (0.8)  |
| Interest expense  | (14) | 43.9   | 66.0   |
| Net foreign exchange (gain) / loss and others                 | (14) | (27.8)                                       | 1.5  |
| Share in income of equity-accounted investees                 |      | (62.9)                                       | (0.7)  |
| Equity-settled share-based payment transactions               |      | 2.2  | 2.0  |
| Impact difference in profit-sharing non-controlling interests |      | 60.3   | 13.0   |
| Income tax expense  |      | 140.0  | 30.1   |
| Changes in:   |      |  |  |
| Inventories   |      | (178.5)                                      | 2.7  |
| Trade and other receivables                                   |      | (190.0)                                      | (150.0)                                      |
| Trade and other payables                                      | (12) | 168.3  | 126.6  |
| Provisions  | (17) | 1.9  | 0.7  |
| Cash flows:   |      |  |  |
| Interest paid   |      | (17.3)                                       | (19.0)                                       |
| Lease interest paid   |      | (2.1)  | (2.2)  |
| Interest received   |      | 2.6  | 0.3  |
| Income taxes paid   |      | (57.4)                                       | (32.5)                                       |
| Cash flow from operating activities                           |      | 725.7  | 372.4  |
| Investments in property, plant and equipment                  |      | (51.4)                                       | (56.9)                                       |
| Dividends from equity-accounted investees                     |      | ()   | (00.0)                                       |
| Cash flow used in investing activities                        |      | (51.4)                                       | (56.9)                                       |

## **CONSOLIDATED STATEMENT OF CASH FLOWS** CONTINUED FOR THE THREE-MONTH PERIOD ENDED 31 MARCH

| \$ millions  | Note | Three-month<br>period ended<br>31 March 2022 | Three-month<br>period ended<br>31 March 2021 |
|--|------|--|--|
| Proceeds from borrowings                                     | (11) | 0.2  | 367.4  |
| Repayment of borrowings                                      | (11) | (552.3)                                      | (540.4)                                      |
| Payment of lease obligations                                 |      | (7.6)  | (7.1)  |
| Purchase of treasury shares                                  |      | (0.2)  | -  |
| Newly incurred transaction costs / call premium              |      | (0.4)  | (5.9)  |
| Dividends paid to non-controlling interests                  |      | (66.7)                                       | -  |
| Proceeds from sale of shares in OCI Methanol Group           | (10) | 375.0  | -  |
| Fees related to the sale of shares in OCI Methanol Group     | (10) | (1.3)  | -  |
| Settlement FX derivatives                                    |      | 2.6  | (41.3)                                       |
| Cash flows used in financing activities                      |      | (250.7)                                      | (227.3)                                      |
| Net cash flow  |      | 423.6  | 88.2   |
| Net increase in cash and cash equivalents                    |      | 423.6  | 88.2   |
| Cash and cash equivalents at start of period                 |      | 1,197.3                                      | 686.3  |
| Effect of exchange rate fluctuations on cash held            |      | (30.0)                                       | (4.4)  |
| Cash and cash equivalents at 31 March                        |      | 1,590.9                                      | 770.1  |
| Cash and cash equivalents in statement of financial position |      | 1,759.0                                      | 770.1  |
| Bank overdraft repayable on demand                           |      | (168.1)                                      | -  |
| Cash and cash equivalents in statement of cash flows         |      | 1,590.9                                      | 770.1  |

#### 1. General

OCI N.V. ('OCI' or 'Company') was established on 2 January 2013 as a public limited liability company incorporated under Dutch law, with its head office located at Honthorststraat 19, Amsterdam, the Netherlands. OCI is registered in the Dutch commercial register under no. 56821166 dated 2 January 2013. The quarterly condensed consolidated financial statements comprise the financial statements of the Company, its subsidiaries (together referred to as the 'Group') and the Group's interests in associates and joint ventures.

The Group is primarily involved in the production of natural gas-based products.

#### 2. Basis of preparation

The quarterly condensed consolidated financial statements for the period ended 31 March 2022 have been prepared according to the same accounting policies as our most recent annual financial statements and do not include all the information and disclosures required in the annual financial statements. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at and for the year ended 31 December 2021. The quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended 31 December 2021 which have been prepared in accordance with IFRS, as adopted by the European Union.

These quarterly condensed consolidated financial statements have not been audited or reviewed by our external auditor.

#### 3. Summary of significant accounting policies

The accounting policies applied over the three-month period ended 31 March 2022 are consistent with those applied in the consolidated financial statements for the year ended 31 December 2021. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

IFRS standards and interpretations thereof not yet in force which may apply to the future Group's consolidated financial statements are being assessed for their potential impact. Currently there are no standards and interpretations not yet effective that would have a significant impact on the Group.

#### 4. Seasonality of operations

Our product portfolio is diversified primarily by industry and geography. The nitrogen fertilizer industry is inherently dependent on fundamental supply and demand drivers, including global population growth, crop yields, feedstock costs, and seasonality of crop planting and harvesting seasons. These and other long-term and short-term drivers result in cyclical nitrogen fertilizer pricing trends. Supply and demand dynamics in the industrial chemicals industries in which we operate, including industrial ammonia, methanol, and melamine, are more evenly distributed throughout the year, thereby contributing to stability in sales volumes. The global sales and diversified product mix - both as fertilizers and chemical products - mitigate the impact of any one product or region's seasonal fluctuations.

#### 5. Critical accounting judgment, estimates and assumptions

The preparation of the financial statements in compliance with IFRS requires management to make judgements, estimates and assumptions that affect amounts reported in the condensed consolidated financial statements. The estimates and assumptions are based on experience and various other factors that are believed to be reasonable under the circumstances and are used to judge the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised or in the revision period and future periods, if the changed estimates affect both current and future periods.

Compared to the consolidated financial statements for the year ended 31 December 2021 there were no significant changes to the critical accounting judgements, estimates and assumptions that could result in significantly different amounts than those recognized in the financial statements.

With respect to financial instruments, there has not been any reclassification between categories of financial instruments compared to the consolidated financial statements for the year ended 31 December 2021. The objectives and policies of financial risk and capital management are consistent with those disclosed in the consolidated financial statements for the year ended 31 December 2021.

#### 6. Significant rates

The following significant exchange rates applied during the period:

|                | Average during the<br>three-month period<br>ended 31 March 2022 | Average during the<br>three-month period<br>ended 31 March 2021 | Closing as at 31 March 2022 | Closing as at<br>31 December 2021 |
|----------------|---|---|-----------------------------|-----------------------------------|
| Euro           | 1.1220  | 1.2050  | 1.1082                      | 1.1370                            |
| Egyptian pound | 0.0623  | 0.0637  | 0.0547                      | 0.0636                            |
| Algerian dinar | 0.0071  | 0.0075  | 0.0070                      | 0.0072                            |

#### 7. Financial risk and capital management

7.1 Financial risk management

#### Categories of financial instruments:

| 31 March 2022<br>\$ million            | Loans and<br>receivables /<br>payables at<br>amortized cost | Derivatives at fair value | Financial assets at fair<br>value through other<br>comprehensive income |
|--|---|---------------------------|---|
| Assets                                 |   |                           |   |
| Trade and other receivables            | 1,011.3   | 81.5                      | -   |
| Financial assets at fair value through |   |                           |   |
| other comprehensive income             | -   | -                         | 21.7  |
| Cash and cash equivalents              | 1,759.0   | -                         | -   |
| Total                                  | 2,770.3   | 81.5                      | 21.7  |
| Liabilities                            |   |                           |   |
| Loans and borrowings                   | 3,019.5   | -                         | -   |
| Trade and other payables               | 1,615.3   | 110.5                     | -   |
| Total                                  | 4,634.8   | 110.5                     | -   |

| Loans and<br>receivables<br>/ payables<br>at amortized<br>cost | Derivatives<br>at fair value  | Financial assets at fair<br>value through other<br>comprehensive income   |
|--|---|---|
|  |   |   |
| 831.8  | 53.4  | -   |
| -  | -   | 19.2  |
| 1,580.3  | -   | -   |
| 2,412.1  | 53.4  | 19.2  |
|  |   |   |
| 3,800.8  | -   | -   |
| 1,252.2  | 129.0   | -   |
| 5,053.0  | 129.0   | -   |
|  | receivables<br>/ payables<br>at amortized<br>cost<br>831.8<br>-<br>1,580.3<br>2,412.1<br>3,800.8<br>1,252.2 | / payables<br>at amortized<br>cost         Derivatives<br>at fair value           831.8         53.4           -         -           1,580.3         -           2,412.1         53.4           3,800.8         -           1,252.2         129.0 |

The Group has several financial instruments carried at fair value. For derivative financial instruments, the fair value is calculated within hierarchy category level 2. Financial assets at fair value through other comprehensive income recognized as level 1 is USD 2.6 million (2021: USD 2.8 million), the investment in the Infrastructure and Growth Capital Fund of USD 2.3 million (2021: USD 2.8 million) was recognized as level 2 as the valuation is partially derived from listed shares. The investment in Notore Chemical Industries of USD 16.8 million (2021: USD 13.6 million) is recognized as level 3.

Notore was listed on the Nigerian Stock Exchange in 2018, however due to the lack in trading volumes the investment is still valued within the hierarchy category level 3 based on published financial statements.

In 2022 and 2021, there were no transfers between the fair value hierarchy categories. The carrying amounts of financial assets and liabilities carried at amortized cost (loans and borrowings, trade and other receivables and trade and other payables) approximates their fair values.

For a general description of the risks related to financial instruments, reference is made to the 2021 consolidated financial statements.

#### 7.2 Capital management

The Board's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Capital consists of ordinary shares, retained earnings and non-controlling interests of the Group. The Board of Directors monitors the return on capital as well as the level of dividends to ordinary shareholders. The Group is required by external financial institutions to maintain certain capital requirements compared to its debt.

The Group's net debt to equity ratio at the reporting date was as follows:

| \$ millions                     | 31 March<br>2022 | 31 December<br>2021 |
|---------------------------------|------------------|---------------------|
| Loans and borrowings            | 3,019.5          | 3,800.8             |
| Less: cash and cash equivalents | 1,759.0          | 1,580.3             |
| Net debt                        | 1,260.5          | 2,220.5             |
| Total equity                    | 4,380.4          | 3,508.2             |
| Net debt to equity ratio        | 0.29             | 0.63                |

#### 8. Property, plant and equipment

|                                      | Land and  | Plant and | Fixtures and | Under        |           |
|--------------------------------------|-----------|-----------|--------------|--------------|-----------|
| \$ millions                          | buildings | equipment | fittings     | construction | Total     |
| Cost                                 | 751.9     | 9,328.1   | 60.4         | 146.2        | 10,286.6  |
| Accumulated depreciation             | (185.7)   | (3,813.7) | (42.9)       | -            | (4,042.3) |
| At 1 January 2021                    | 566.2     | 5,514.4   | 17.5         | 146.2        | 6,244.3   |
| Movements in the carrying amount:    |           |           |              |              |           |
| Additions                            | 2.0       | 25.1      | 4.8          | 203.3        | 235.2     |
| Disposals                            | -         | (2.4)     | -            | -            | (2.4)     |
| Depreciation                         | (24.8)    | (531.8)   | (3.5)        | -            | (560.1)   |
| Impairment                           | (1.3)     | (244.7)   | (0.3)        | (30.0)       | (276.3)   |
| Transfers                            | 0.6       | 163.0     | 1.2          | (164.8)      | -         |
| Reclassification to inventory        | -         | (19.0)    | -            | -            | (19.0)    |
| Asset retirement obligation          | -         | -         | 8.7          | -            | 8.7       |
| Effect of movement in exchange rates | (3.2)     | (76.1)    | (0.7)        | (6.9)        | (86.9)    |
| At 31 December 2021                  | 539.5     | 4,828.5   | 27.7         | 147.8        | 5,543.5   |
| Cost                                 | 748.6     | 9,208.8   | 73.8         | 147.8        | 10,179.0  |
| Accumulated depreciation             | (209.1)   | (4,380.3) | (46.1)       | -            | (4,635.5) |
| At 1 January 2022                    | 539.5     | 4,828.5   | 27.7         | 147.8        | 5,543.5   |
| Movements in the carrying amount:    |           |           |              |              |           |
| Additions                            | 0.8       | 12.8      | 0.5          | 24.3         | 38.4      |
| Disposals                            | -         | (0.4)     | -            | -            | (0.4)     |
| Depreciation                         | (7.4)     | (120.2)   | (1.0)        | -            | (128.6)   |
| Impairment                           | -         | (6.5)     | -            | -            | (6.5)     |
| Transfers                            | 0.1       | 7.3       | 0.2          | (7.6)        | -         |
| Asset retirement obligation          | -         | -         | 0.6          | -            | 0.6       |
| Effect of movement in exchange rates | (1.5)     | (23.5)    | (0.5)        | (2.9)        | (28.4)    |
| At 31 March 2022                     | 531.5     | 4,698.0   | 27.5         | 161.6        | 5,418.6   |
| Cost                                 | 742.3     | 9,178.9   | 74.2         | 161.6        | 10,157.0  |
| Accumulated depreciation             | (210.8)   | (4,480.9) | (46.7)       | -            | (4,738.4) |
| At 31 March 2022                     | 531.5     | 4,698.0   | 27.5         | 161.6        | 5,418.6   |

#### 9. Goodwill and other intangible assets

No impairment test was performed for goodwill, as no impairment triggers were identified. The annual goodwill impairment test will be performed in the fourth quarter.

#### 10. Non-controlling interests

#### OCI Methanol Group

On 18 February 2022, a 15% stake of the OCI Methanol Group was sold for a total consideration of USD 375.0 million. As a result of this transaction OCI's share in the OCI Methanol Group decreased from 100% to 85%. The following table summarises the effect of the transaction on the Company's equity attributable to owners of the Company:

| \$ millions  | 31 March<br>2022 |
|--|------------------|
| Proceeds from sale of shares                           | 375.0            |
| Fees related to the sale of shares                     | (1.3)            |
| Fair value of earn-out consideration                   | (17.1)           |
| Net proceeds from the sale of shares                   | 356.6            |
| Non-controlling interests                              | 135.2            |
| Effect on equity attributable to owners of the Company | 221.4            |

#### 11. Loans and borrowings

| \$ millions   | 31 March<br>2022 | 31 December<br>2021 |
|---|------------------|---------------------|
| At 1 January  | 3,800.8          | 4,416.6             |
| Proceeds from loans                                 | 0.2              | 2,248.3             |
| Repayment / proceeds from bank overdraft facility   | (208.7)          | 398.4               |
| Repayment and redemption of loans and borrowings    | (552.3)          | (3,186.1)           |
| Newly incurred transaction costs                    | -                | (10.0)              |
| Amortization of transaction costs / (bond) premiums | 5.2              | 39.3                |
| Effect of movement in exchange rates                | (25.7)           | (105.7)             |
| Balance at  | 3,019.5          | 3,800.8             |
| Non-current   | 2,724.1          | 3,290.2             |
| Current   | 295.4            | 510.6               |
| Total   | 3,019.5          | 3,800.8             |

#### 11. Loans and borrowings (continued)

The effect of movement in exchange rate mainly relates to EUR and DZD denominated loans, which are different from the Group's presentation currency. There are no new or amended financing arrangements during the period ended 31 March 2022.

#### Covenants

Certain loan agreements include financial covenants. As per 31 March 2022 all financial covenants were met. In the event the respective borrowing companies would not comply with the covenant requirements, its loans would become immediately due.

#### 12. Trade and other payables

| \$ millions  | 31 March<br>2022 | 31 December<br>2021 |
|--|------------------|---------------------|
| Trade payables                                     | 442.3            | 425.3               |
| Trade payables due to related parties              | 75.8             | 87.9                |
| Amounts payable under the securitization agreement | 186.6            | 149.7               |
| Accrued dividend to non-controlling interests      | 186.3            | 4.1                 |
| Other payables                                     | 77.3             | 66.9                |
| EUA liabilities                                    | 108.1            | 116.2               |
| Employee benefit liabilities                       | 14.3             | 14.5                |
| Accrued expenses                                   | 278.8            | 264.9               |
| Accrued interest                                   | 28.6             | 10.9                |
| Customer advance payment / deferred revenue        | 320.1            | 222.7               |
| Other tax payable                                  | 5.2              | 5.3                 |
| Commodity derivative financial instruments         | 2.4              | 12.8                |
| Total  | 1,725.8          | 1,381.2             |
| Non-current  | 129.9            | 23.7                |
| Current  | 1,595.9          | 1,357.5             |
| Total  | 1,725.8          | 1,381.2             |

#### Accrued dividend to non-controlling interests

The increase in accrued dividend to non-controlling interests is primarily driven by the minimum dividend liability of USD 144.5 million recorded as a result of the 15% sale of OCI Methanol Group. The Company has agreed with the buyers a yearly guaranteed dividend for the period 2022-2025.

#### 13. Development of cost of sales and selling, general and administrative expenses

| \$ millions                                      | 31 March<br>2022 | 31 March<br>2021 |
|--|------------------|------------------|
| Raw materials and consumables and finished goods | 1,212.4          | 533.0            |
| Maintenance and repair                           | 44.2             | 35.7             |
| Employee benefit expenses                        | 106.2            | 98.6             |
| Depreciation, amortization and impairment        | 146.0            | 150.2            |
| Consultancy expenses                             | 10.4             | 7.4              |
| Other  | 23.5             | 14.9             |
| Total  | 1,542.7          | 839.8            |
| Cost of sales                                    | 1,464.3          | 779.2            |
| Selling, general and administrative expenses     | 78.4             | 60.6             |
| Total  | 1,542.7          | 839.8            |

Depreciation, amortization and impairment includes an impairment loss of USD 6.5 million related to BioMCN.

#### 14. Net finance cost

| \$ millions  | 31 March<br>2022 | 31 March<br>2021 |
|--|------------------|------------------|
| Interest income on loans and receivables                                     | 0.5              | 0.8              |
| Derivatives gain   | 2.2              | -                |
| Foreign exchange gain  | 69.5             | 7.3              |
| Finance income   | 72.2             | 8.1              |
| Interest expense and other financing costs on financial liabilities measured |                  |                  |
| at amortized cost  | (43.9)           | (66.0)           |
| Foreign exchange loss  | (41.7)           | (8.8)            |
| Finance cost   | (85.6)           | (74.8)           |
| Net finance cost recognized in profit or loss                                | (13.4)           | (66.7)           |

The increase in foreign exchange gains and losses are mainly driven by the depreciation of the Egyptian Pound and Euro against the US Dollar in the first quarter of 2022, compared to a more stable environment in the first guarter of 2021.

Further increases to foreign exchange gains, is driven by intercompany loans no longer being designated to form part of the net investment in foreign operations, as compared to same period in the prior year. The effect of the change in accounting treatment is that foreign exchange gains or losses on intercompany loans are recognised in profit or loss, instead of other comprehensive income.

#### 15. Income taxes

The Group's consolidated effective tax rate in respect of continuing operations for the three-month period ended 31 March 2022 was 16.7% (for the three-month period ended 31 March 2021: 17.6%). Compared to the statutory tax rate applicable in the Netherlands (25.8%) the following elements are the main driver for the lower effective tax rate:

• Higher profits generated by the export activities of Sorfert and increased profitability of EBIC for the three-month period ended 31 March 2022 resulted in a lower effective tax rate compared to the same period in 2021.

• As a result of the increased profitability of Natgasoline, net operating losses that were previously unrecognized could be utilized. This results in a decrease of the effective tax rate.

• The before mentioned was partially offset by non-deductible expenses which are mainly related to restrictions on interest-deductions and shareholder costs and by deferred tax effects of undistributed earnings of subsidiaries.

#### 16. Segment reporting

| 31 March 2022<br>\$ millions                                | Methanol<br>US | Methanol<br>Europe | Nitrogen<br>US | Nitrogen<br>Europe | Fertiglobe     | Other          | Eliminations   | Total          |
|---|----------------|--------------------|----------------|--------------------|----------------|----------------|----------------|----------------|
| \$ IIIIIIOIIS   | 03             | Europe             | 03             | Europe             | renigione      | Other          | Emmations      | TOTAL          |
| Total revenues  | 257.5          | 135.1              | 453.7          | 553.3              | 1,184.8        | -              | (256.6)        | 2,327.8        |
| EBITDA <sup>2</sup>   | 192.1          | 9.9                | 152.6          | 76.0               | 619.6          | (27.0)         | (87.5)         | 935.7          |
| Adjusted EBITDA <sup>2</sup>                                | 134.9          | 9.9                | 152.6          | 76.3               | 624.6          | (27.0)         | (1.2)          | 970.1          |
| Income from equity-<br>accounted investees<br>Depreciation, | -              | -                  | -              | 2.1                | -              | -              | 60.8           | 62.9           |
| amortization and impairment                                 | (37.0)         | (9.0)              | (37.5)         | (18.2)             | (62.0)         | (1.3)          | 19.0           | (146.0)        |
| Finance income<br>Finance expense                           | 2.1<br>(7.5)   | -<br>0.2           | 0.1<br>(22.5)  | 4.4<br>(6.0)       | 35.8<br>(36.3) | 40.8<br>(31.6) | (11.0)<br>18.1 | 72.2<br>(85.6) |
| Income tax<br>(expense) / income                            | (22.1)         | (0.4)              | (17.7)         | (14.6)             | (90.0)         | 5.1            | (0.3)          | (140.0)        |
| Net profit / (loss)   | 127.6          | 0.7                | 75.0           | 43.7               | 467.1          | (14.0)         | (0.9)          | 699.2          |
| Equity-accounted investees                                  | -              | -                  | -              | 42.9               | -              | 0.2            | 520.2          | 563.3          |
| Capital expenditures<br>PP&E                                | 84.1           | 8.3                | 1.3            | 6.7                | 9.1            | 1.9            | (73.0)         | 38.4           |
| Total assets  | 1,617.6        | 115.9              | 2,634.1        | 854.1              | 5,428.1        | 165.1          | (520.1)        | 10,294.8       |

#### 16. Segment reporting (continued)

| <b>31 March 2021</b><br>\$ millions                            | Methanol<br>US <sup>1 3</sup> | Methanol<br>Europe | Nitrogen<br>US <sup>3</sup> | •      | Fertiglobe <sup>3</sup> | Other <sup>3</sup> E | Eliminations <sup>3</sup> | Total   |
|--|-------------------------------|--------------------|-----------------------------|--------|-------------------------|----------------------|---------------------------|---------|
|  |                               | -                  |                             | -      | -                       |                      |                           |         |
| Total revenues   | 144.3                         | 142.4              | 103.9                       | 220.2  | 543.4                   | -                    | (34.6)                    | 1,119.6 |
| EBITDA <sup>2</sup>  | 115.6                         | 19.1               | 79.7                        | 26.4   | 230.8                   | (13.7)               | (27.1)                    | 430.8   |
| Adjusted EBITDA <sup>2</sup>                                   | 108.1                         | 19.1               | 79.7                        | 26.4   | 230.8                   | (13.7)               | 1.4                       | 451.8   |
| Income from equity-<br>accounted investees<br>Depreciation and | -                             | -                  | -                           | 0.8    | -                       | -                    | (0.1)                     | 0.7     |
| amortization   | (39.3)                        | (7.4)              | (35.7)                      | (24.6) | (63.8)                  | (0.9)                | 21.5                      | (150.2) |
| Finance income   | 16.0                          | -                  | 0.1                         | 2.5    | 5.1                     | 18.0                 | (33.6)                    | 8.1     |
| Finance expense  | (23.2)                        | (0.7)              | (39.4)                      | (3.1)  | (10.6)                  | (38.4)               | 40.6                      | (74.8)  |
| Income tax<br>(expense) / income                               | (2.4)                         | 0.1                | (0.6)                       | (0.3)  | (27.0)                  | 0.1                  | -                         | (30.1)  |
| Net profit / (loss)  | 66.7                          | 11.1               | 4.1                         | 1.7    | 134.5                   | (34.9)               | 1.3                       | 184.5   |
| Equity-accounted investees                                     | -                             | -                  | -                           | 15.8   | -                       | 0.2                  | 452.8                     | 468.8   |
| Capital expenditures<br>PP&E                                   | 4.9                           | 2.3                | 4.7                         | 7.2    | 6.8                     | 0.2                  | (3.2)                     | 22.9    |
| Total assets   | 1,572.5                       | 416.7              | 2,214.7                     | 715.4  | 4,723.2                 | 92.8                 | (596.6)                   | 9,138.7 |

#### <sup>1</sup> Including ammonia at OCIB

<sup>2</sup> OCI N.V. uses Alternative Performance Measures ('APM') to provide a better understanding of the underlying developments of the performance of the business. The APMs are not defined in IFRS and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. The definition of the APM and a detailed reconciliation between the APM and the most directly comparable IFRS measure can be found on pages 14 - 15 of the report.

<sup>3</sup> The comparative numbers of 2021 are restated to reflect the realignment of the Fertiglobe, Methanol US, Nitrogen US and Other segments.

#### 17. Provisions, contingent assets and liabilities

There have been no significant changes in provisions, contingent assets and liabilities compared to the situation as described in the consolidated financial statements for the year ended 31 December 2021.

#### 18. Subsequent events

#### OCI refinancing activities

On 8 April 2022, OCI announced that it has closed a new unsecured multicurrency Revolving Credit Facility ("RCF") for a total of USD 1.1 billion, which will replace a facility of USD 850 million, which was undrawn at the time of refinancing and originally entered into in 2018. The new facility carried an interest margin at inception of 1.10% and has a tenor of 60 months.

On 22 April 2022, OCI announced that its wholly-owned subsidiary lowa Fertilizer Company ("IFCo") has priced a transaction to refinance in full its outstanding capital markets debt. The transaction involves the offering by the lowa Finance Authority of USD 838.8 million Midwestern Disaster Area Revenue Refunding Bonds (lowa Fertilizer Company Project), Series 2022. The Series 2022 Bonds include:

- USD 150.0 million 10-year par bond with 4.00% coupon;
- USD 344.4 million 20-year premium bond with 5.0% coupon yielding 4.65%; and
- USD 344.4 million 28-year premium bond with 5.0% coupon yielding 4.80%.

The Series 2022 Bonds will bear interest at a weighted average cost of capital of 4.60% per annum, payable semi-annually, and an average life of 22 years. OCI anticipates to incur approximately USD 50 million of redemption fees in relation to this refinancing.

#### Fertiglobe interim dividends

In April 2022, Fertiglobe paid out interim dividends of USD 340 million to Fertiglobe shareholders. OCI's share amounts to USD 170 million.

## ALTERNATIVE PERFORMANCE MEASURES (APMs)

OCI presents certain financial measures when discussing OCI's performance, that are not measures of financial performance under IFRS. These non-IFRS measures of financial performance (also known as non-GAAP or alternative performance measures) are presented because management considers them important supplemental measures of OCI's performance and believes that similar measures are widely used in the industry in which OCI operates. OCI believes that an understanding of its financial performance is enhanced by reporting the following APMs:

- EBITDA
- Adjusted EBITDA
- Adjusted net profit
- Free cash flow

EBITDA, adjusted EBITDA, adjusted net profit and free cash flow are supplemental measures of financial performance that are not required by, or presented in accordance with, IFRS. Therefore, EBITDA, adjusted EBITDA, adjusted net profit and free cash flow should be viewed as supplemental but not as a substitute for measures presented in the Consolidated Statement of Profit or Loss and Other Comprehensive Income, which are determined in accordance with IFRS.

External stakeholders should not consider EBITDA, adjusted EBITDA, adjusted net profit and free cash flow (a) as an alternative to operating profit or profit before taxation (as determined in accordance with IFRS) as a measure of our operating performance, and (b) as an alternative to any other measure of performance under IFRS. Because not all companies define adjusted EBITDA, EBITDA, adjusted net profit and free cash flow in the same way, these measures may not be comparable to similarly titled measures used by other companies.

Definitions and explanations of the use of the APMs are described below. Reconciliations of the APMs to the most directly reconcilable line item are presented on the following pages.

#### **EBITDA**

EBITDA is defined as the total net profit before interest, income tax expenses, depreciation and amortization, foreign exchange gains and losses and income from equity accounted investees.

#### **Adjusted EBITDA**

Adjusted EBITDA is defined as EBITDA, adjusted for additional items and costs that management considers not reflective of our core operations.

#### Adjusted net profit

Adjusted net profit is the total net profit, adjusted for additional items and costs that management considers not reflective of our core operations.

#### Free cash flow

Free cash flow (FCF) reflects an additional way of viewing our liquidity that we believe is useful to our investors and is defined as cash flow reflecting the EBITDA for the year, change in working capital, maintenance capital expenditure, taxes paid, cash interest paid, lease payments, dividends from equity accounted investees, dividends paid to non-controlling interests and adjustment for other non-cash items.

#### Reconciliation of operating profit to adjusted EBITDA for the three-month period ended:

| \$ million                                | 31 March 2022 | 31 March 2021 |
|---|---------------|---------------|
| Operating profit                          | 789.7         | 280.6         |
| Depreciation, amortization and impairment | 146.0         | 150.2         |
| EBITDA                                    | 935.7         | 430.8         |
| APM adjustments                           | 34.4          | 21.0          |
| Adjusted EBITDA                           | 970.1         | 451.8         |

#### APM adjustments at EBITDA level

| \$ million                            | 31 March 2022 | 31 March 2021 |
|---------------------------------------|---------------|---------------|
| Natgasoline                           | 37.1          | 24.3          |
| Unrealized result natural gas hedging | (16.5)        | (3.3)         |
| Other including provisions            | 13.8          | -             |
| Total APM adjustments at EBITDA level | 34.4          | 21.0          |

## ALTERNATIVE PERFORMANCE MEASURES (APMs) CONTINUED

#### The main APM adjustments at EBITDA level in YTD Q1 2022 and YTD Q1 2021 relate to:

- Natgasoline is not consolidated and an adjustment of USD 37.1 million was made for OCI's 50% share in the plant's EBITDA in 2022. Natgasoline's contribution to adjusted EBITDA in 2021 was USD 24.3 million.
- The unrealized results on natural gas hedge derivatives of USD (16.5) million in 2022 and USD (3.3) million in 2021 relate to hedging activities at OCI Beaumont and in the Netherlands.
- Other adjustments of USD 13.8 million in 2022 mainly relates to movements in provisions related to
  ongoing litigation and claims and other adjustments.

| \$ million  | 31 March 2022 | 31 March 2021 |
|---|---------------|---------------|
| Reported net profit attributable to owners of the Company       | 409.7         | 98.6          |
| Adjustments at EBITDA level                                     | 34.4          | 21.0          |
| Add back: Natgasoline EBITDA adjustment                         | (37.1)        | (24.3)        |
| Result from associate (change in unrealized gas hedging Natgas) | (49.3)        | (4.2)         |
| Forex (gain) / loss on USD exposure                             | (32.2)        | (0.2)         |
| Impairment of BioMCN  | 6.5           | -             |
| Expenses related to refinancing                                 | 0.9           | 8.0           |
| Non-controlling interests adjustment                            | 15.2          | 3.3           |
| Tax effect of adjustments                                       | 6.1           | 0.2           |
| Total APM adjustments at net profit level                       | (55.5)        | 3.8           |
| Adjusted net profit attributable to owners of the Company       | 354.2         | 102.4         |

#### The main APM adjustments at net profit level in YTD Q1 2022 and YTD Q1 2021 relate to:

- The adjustment on result from associate of USD (49.3) million in 2022 and USD (4.2) million in 2021 mainly relates to the unrealized results on natural gas hedge derivatives at Natgas.
- FX impact of USD (32.2) million in 2022 and USD (0.2) million in 2021 relates to the foreign exchange gains or losses on loans and borrowings and related instruments on USD exposure carried at entities which do not have USD as functional currency.
- Impairment of USD 6.5 million in 2022 relates to the impairment of BioMCN.
- Refinancing expenses of USD 0.9 million in 2022 and USD 8.0 million in 2021 relates to early redemption costs and accelerated amortization, mainly at OCI N.V. and IFCo.
- Non-controlling interests adjustment of USD 15.2 million in 2022 and USD 3.3 million in 2021 is related to the calculated profit attributable to non-controlling interests on all APM adjustments.
- Tax effect of adjustments of USD 6.1 million in 2022 and USD 0.2 million in 2021 is related to the calculated tax effect of all APM adjustments.

#### Free cash flow

| \$ million                                  | 31 March 2022 | 31 March 2021 |
|---|---------------|---------------|
| Cash flow from operating activities         | 725.7         | 372.4         |
| Maintenance capital expenditure             | (44.2)        | (55.9)        |
| Lease payments                              | (7.6)         | (7.1)         |
| Dividends paid to non-controlling interests | (66.7)        | -             |
| Other non-operating items                   | 2.1           | 16.2          |
| Free cash flow                              | 609.3         | 325.6         |